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Expression, purification and characterization of
soluble red rooster laforin as a fusion protein in
Escherichia coli
M Kathryn Brewer, Satrio Husodo, Vikas V Dukhande, Mary Beth Johnson and Matthew S Gentry*

Abstract
Background: The gene that encodes laforin, a dual-specificity phosphatase with a carbohydrate-binding module, is
mutated in Lafora disease (LD). LD is an autosomal recessive, fatal progressive myoclonus epilepsy characterized
by the intracellular buildup of insoluble, hyperphosphorylated glycogen-like particles, called Lafora bodies. Laforin
dephosphorylates glycogen and other glucans in vitro, but the structural basis of its activity remains unknown.
Recombinant human laforin when expressed in and purified from E. coli is largely insoluble and prone to aggregation
and precipitation. Identification of a laforin ortholog that is more soluble and stable in vitro would circumvent this issue.
Results: In this study, we cloned multiple laforin orthologs, established a purification scheme for each, and tested
their solubility and stability. Gallus gallus (Gg) laforin is more stable in vitro than human laforin, Gg-laforin is largely
monomeric, and it possesses carbohydrate binding and phosphatase activity similar to human laforin.
Conclusions: Gg-laforin is more soluble and stable than human laforin in vitro, and possesses similar activity as a
glucan phosphatase. Therefore, it can be used to model human laforin in structure-function studies. We have
established a protocol for purifying recombinant Gg-laforin in sufficient quantity for crystallographic and other
biophysical analyses, in order to better understand the function of laforin and define the molecular mechanisms of
Lafora disease.
Keywords: Laforin, Lafora disease, Phosphatase, Carbohydrate-binding module, Glycogen

Background
Lafora disease (LD) is an autosomal recessive, neurodegenerative disorder resulting in myoclonus, epilepsy, dementia, and death [1-3]. Affected individuals experience an
initial seizure during adolescence, followed by severe neurological decline until the patient’s death approximately ten
years after the first seizure [1,4]. Characteristic of the disease is the cytoplasmic accumulation of hyperphosphorylated glycogen-like particles called Lafora bodies (LBs) in
various tissues including brain, muscle and liver [1,5].
Approximately 50% of Lafora disease cases are caused
by mutations in the EPM2A (epilepsy of progressive
myoclonus type 2 gene A) gene that encodes the protein
laforin [4-6]. EPM2A is conserved in all vertebrate genomes, but it is absent from the genome of most non* Correspondence: matthew.gentry@uky.edu
Department of Molecular and Cellular Biochemistry and Center for Structural
Biology, College of Medicine, University of Kentucky, 741 S. Limestone,
Lexington, Kentucky 40536-0509, USA

vertebrate organisms including standard model organisms such as Saccharomyces cerevisiae, Caenorhabditis
elegans, and Drosophila melanogaster [7,8]. An exception
to this rule is a small subgroup of protists that synthesize
floridean starch, an insoluble carbohydrate similar to LBs.
Five protozoan laforin orthologs have been identified;
however, sequence identity between these proteins and
human laforin is <37% and the genes have major insertions and deletions [7,8]. Thus, these proteins are not optimal orthologs to utilize for modeling human laforin.
Laforin is a bimodular protein with a carbohydratebinding module (CBM) at its amino-terminus and a
dual-specificity phosphatase (DSP) domain at its carboxyterminus [9-11]. CBMs are most commonly found in glycosyl hydrolases and glucosyl transferases from bacteria, fungi
or plants, and there are over 39 families of CBMs that bind
a variety of carbohydrate substrates. Laforin belongs to the
CBM20 family according to the Carbohydrate-Active Enzymes (CAZy; www.cazy.org) database [12]. CBM20s are
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closely related to CBM48s, and both are classified as
starch-binding domains with similar folds and binding
sites [13-15]. Typical of DSPs, laforin is capable of
hydrolyzing phosphotyrosine and phosphoserine/phosphothreonine substrates; however, laforin is unique
among phosphatases in that it is the only phosphatase
in humans containing a CBM, which targets laforin to
glycogen [8,9]. Laforin has been shown to bind and dephosphorylate glycogen and other glucans in vitro and
in vivo [8,9,16-19].
Glycogen is an energy storage molecule synthesized by
bacterial, fungal and animal species consisting of α-1,4
and α-1,6 linked residues of glucose, with 12-14 residues
per branch [20]. Glycogen has been shown to contain
small amounts of phosphate, but the regulation and effects of this phosphorylation event are currently under
debate [19,21-25]. While the source of phosphorylation
is disputable, data from multiple labs has clearly established that loss of laforin activity results in hyperphosphorylation and poorly branched glycogen, resulting in
insoluble LBs [17-19,23,26].
Although the substrate and function of laforin have recently been elucidated, the structural basis for the unique
glucan phosphatase activity of laforin remains unknown.
Ourselves and others have experienced difficulty purifying
laforin in sufficient quantities and of sufficient quality for
crystallographic studies [27]. One group recently demonstrated that recombinant human laforin expressed in E.
coli is largely insoluble and must be purified from inclusion bodies [27]. This procedure requires denaturation
and refolding steps, involves harsh chemical treatments,
and often yields low amounts of correctly folded protein.
A subsequent report demonstrated that only the laforin
CBM was soluble when expressed in E. coli [28].
Our lab has purified enough recombinant laforin from
the soluble portion of bacterial cell lysates to perform
in vitro assays [8,16,29-31]. However, the protein often
aggregates and precipitates after the multistep purification procedure. In this study, we found that the addition
of sugars to the lysis and purification buffers increases
the yield of soluble laforin from lysates and improves
stability. However, such additives interfere with methods
such as isothermal titration calorimetry that directly
measure protein-ligand interactions. Also, we have been
unable to crystallize laforin purified in the presence of
sugars (unpublished data). Our group recently determined the structures of two glucan phosphatases from
Arabidopsis that are functionally similar to laforin, and
the structures of other DSP domains and CBMs are
available [32,33]. However, these structures provide little
information about the function of laforin due to low
similarity between these domains and the domains of
laforin. We then sought a laforin ortholog that is highly
similar to human laforin (Hs-laforin) and, when expressed
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in bacteria, is less prone to aggregation and precipitation.
We cloned and purified multiple laforin orthologs and
optimized the purification of recombinant Gallus gallus
laforin (Gg-laforin). Previously, the CBM of Gg-laforin
was fused to a glutathione S-transferase (GST) tag and
shown to bind glycogen [34]. In this study, we purified
SUMO-tagged full-length Gg-laforin and confirmed that
Gg-laforin functions as a monomer, contrary to prior
claims that laforin dimerization is necessary for phosphatase activity [27,35]. Phosphatase and glucan binding
assays indicate that the catalytic and binding ability of
Gg-laforin is comparable to that of Hs-laforin [8,30,36].
Therefore, Gg-laforin is an excellent model for Hs-laforin
and a better alternative for crystallization and other biophysical studies.

Results and discussion
Instability of Hs-laforin and other laforin orthologs

Soluble Hs-laforin has proved to be a difficult protein to
purify from E. coli [27,28]. While we have successfully
purified some Hs-laforin suitable for in vitro assays, the
protein is unstable and precipitates from solution. Thus,
we sought to optimize the purification procedure using
an additive. His6-tagged Hs-laforin was expressed and
purified from E. coli by affinity chromatography. Approximately 5 mg of soluble Hs-laforin was obtained
from 1 L of E. coli cells. In order to increase the solubility of Hs-laforin, we tested the addition of the sugars
maltose and β-cyclodextrin (BCD) to the purification
buffer. The addition of 15% maltose (w/v) or 10 mM
BCD to the lysis and purification buffers improved the
yield of soluble Hs-laforin to 8 mg and 9 mg per 1 L culture, respectively (Figure 1A). Next we sought to define
the stability of recombinant Hs-laforin purified in the
different buffers using two methods.
We first determined the stability of Hs-laforin by concentrating the protein using centrifugal filter units and
measuring the volume and concentration throughout
the centrifugation process. The Hs-laforin preparation
without added sugars did not exceed 5 mg/ml and total soluble protein was reduced by 37% during the centrifugation
process (Figure 1B). Conversely, Hs-laforin purified in the
presence of maltose or BCD was concentrated to >11 mg/
ml, and total soluble protein content was reduced by less
than 21% (Figure 1B). Thus, the addition of BCD or maltose allows Hs-laforin to be concentrated to higher concentrations likely by preventing aggregation and precipitation.
Second, we sought to define the long-term stability of
Hs-laforin +/- sugars. Hs-laforin was incubated at room
temperature and protein concentrations were measured
over a period of eight days. After only 12 hours, the
concentration of Hs-laforin had fallen significantly and
continued to drop over the eight-day period (Figure 1C).
With the addition of maltose, the concentration did not
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Figure 1 Purification and stability analysis of Hs-laforin and
Gg-laforin. A. Hs-laforin was expressed in E. coli and purified by
affinity chromatography in the absence (-) and presence of 15%
maltose or 10 mM β-cyclodextrin (BCD). Fractions of the pellet (P)
and supernatant (S) after high-speed centrifugation and fractions of
the IMAC elution (E) were analyzed by SDS-PAGE and stained with
Coomassie Blue dye. B. Elution fractions from Hs-laforin and Gg-laforin
preparations were concentrated using centrifugal filter units. Volume
and concentration of each preparation were monitored throughout
centrifugation, and protein concentration was measured using a
Bradford assay. Total protein content for each preparation before and
after concentration and the percent reduced were calculated for each
preparation. C. Elution fractions were concentrated to approximately
2-4 mg/ml and incubated at room temperature for eight days. The
concentration of each protein was measured during the course of the
experiment using a Bradford assay.

decrease as rapidly, confirming that the addition of maltose improves the stability of laforin over long periods of
time. The addition of BCD improved the stability of
laforin in the first 12 hours, but subsequently the concentration rapidly decreased and Hs-laforin in the presence of
BCD became completely insoluble after 85 hours. Crystallography often demands that proteins be stable at high
concentrations and for extended periods of time. These
data demonstrate that the addition of BCD or maltose inhibits Hs-laforin from precipitating. While these results
represent an improvement over previously reported Hslaforin purification strategies, crystallization trials in our
lab have demonstrated that the presence of BCD or maltose inhibits Hs-laforin crystallization, possibly due to increased heterogeneity in the sample (unpublished data).
While the addition of maltose or BCD increases the stability of Hs-laforin, in addition to inhibiting crystallization,
the presence of a sugar additive would interfere with glucan binding experiments and other biophysical assays.
Therefore, we set out to identify a laforin ortholog that is
similar to Hs-laforin, but more stable in vitro. Sequences
of Hs-laforin and laforin orthologs from Mus musculus
(mouse), Gallus gallus (red rooster), Xenopus tropicalis
(frog), Anolis carolinensis (lizard) and Danio rerio (zebrafish) were aligned using ClustalW. Each of these
orthologs contains the four invariant aromatic residues
characteristic of a laforin CBM (Hs-laforin F5, W32,
W60, and W99) and the signature DSP amino acid sequence, DX30CX2GX2R (Figure 2A). Additionally, these
orthologs are 72-95% similar to Hs-laforin at the amino
acid level (Figure 2B).
We obtained cDNA clones of the EPM2A gene from Mus
musculus (Mm-laforin), Xenopus tropicalis (Xt-laforin), and
Gallus gallus (Gg-laforin). Recombinant Mm-laforin was
expressed with a His6-tag, and Xt-laforin was expressed as a
His6-SUMO fusion protein in E. coli. Mm-laforin and
Xt-laforin were purified in the absence of any sugars and
these preparations yielded more soluble protein than
Hs-laforin, 6 and 10 mg/L of E. coli, respectively. However,
the yield for Mm-laforin was not significantly greater than
Hs-laforin, and Xt-laforin exhibited the same tendency as
Hs-laforin to aggregate and precipitate (Additional file 1:
Figure S1). Gg-laforin was also expressed as a His6-SUMO
fusion protein and purified in the absence of any sugars.
Gg-laforin purifications yielded approximately 14 mg/L of
E. coli, a vast improvement compared to Hs-laforin. We
then investigated the in vitro stability of recombinant
Gg-laforin using the same assays as described for Hs-laforin.
We found that Gg-laforin in the absence of any additive can
be concentrated to over 18 mg/ml, and the protein is stable
>180 hours (Figure 1B-C). Thus, Gg-laforin is much less
prone to precipitation compared to Hs-laforin at high
concentrations and over long periods, and is more favorable
for use in downstream biophysical methods.
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B

Figure 2 Comparison of Hs-laforin with laforin orthologs from five vertebrate species. A. Amino acid sequence alignment of Hs-laforin and
five laforin orthologs. Dark grey indicates identical residues, while similar residues are highlighted in light grey. Resides in red boxes are invariant
residues as defined by the CBM20 family [15]; blue boxes indicate residues that are part of the phosphatase catalytic site. Locations of 42 missense
mutations in Hs-laforin associated with LD are marked with arrows. The numbering of amino acids corresponds to the Hs-laforin sequence. B. Percent
similarity and identity of Hs-laforin compared with laforin orthologs from other vertebrates.

Gg-laforin purification yields a monomeric species

Given recent reports that full-length Hs-laforin cannot be
purified as a soluble protein and our data demonstrating its
instability, we sought to optimize Gg-laforin purification and
to test its biochemical properties to determine whether
Gg-laforin would be a good alternative for solving the laforin

structure [27,28]. Recombinant His6-SUMO-Gg-laforin was
expressed and purified from E. coli by affinity chromatography, digested with ULP1 to cleave the His6-SUMO tag,
and subjected to reverse affinity chromatography to remove
the tag and His6-tagged ULP1. These steps yielded ~10 mg
of untagged Gg-laforin per L of bacterial culture.
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elution fractions. To test if Gg-laforin exists in a dynamic
monomer/dimer state, we collected the fractions from the
monomer peak, concentrated the fractions, and re-loaded
these fractions over the same column. Gg-laforin eluted as
a 36 kDa protein, and no dimer shoulder was present during this second purification, suggesting that monomeric
Gg-laforin does not convert to a dimer (Figure 3B). The
protein content and purity of the Superdex 200 monomeric fraction was assessed by collecting fractions and
analyzing them by SDS-PAGE. Gg-laforin purified via this
multi-step protocol migrated as a highly pure 36 kDa protein (Figure 3C). Previous studies have shown that Hslaforin dimers are resistant to SDS denaturation to a small
extent, but there was no indication from the gel that a
Gg-laforin dimer species was present [30,35]. To further
define the size and oligomeric state of Gg-laforin, the
Superdex 200-purified Gg-laforin protein was analyzed

Hs-laforin has a propensity to dimerize and form multimers [8,30]. In addition to a multimer peak, Hs-laforin
elutes from size exclusion columns as a second peak
with a small shoulder of larger molecular weight [8,30].
The small shoulder contains dimerized Hs-laforin and
the major peak to the right of this shoulder is monomeric Hs-laforin [30]. In order to determine whether
Gg-laforin also forms higher order species, Gg-laforin
was subjected to size exclusion chromatography using a
Superdex 200 column. Similar to Hs-laforin, Gg-laforin
eluted as multiple peaks with a significant amount of
protein in the multimer peak (Figure 3A). The chromatogram for the Gg-laforin elution showed a similar
pattern as previously reported for Hs-laforin with both
a dimer shoulder (~72 kDa) and a monomer peak
(~36 kDa) (Figure 3A). Approximately 5 mg of monomeric Gg-laforin was recovered from the size-exclusion
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Figure 3 Purification and characterization of Gg-laforin. A. The chromatogram is of His6-SUMO- tagged Gg-laforin first purified using an IMAC
affinity column, and then passed over a HiLoad 16/60 Superdex 200 size exclusion column. Calibration of molecular weight markers is indicated,
and ordinates indicate the natural logarithm of molecular weight (Mr). B. The monomer fractions were collected, concentrated, and re-loaded
over the same column. The chromatogram shows the results of this second round of size-exclusion chromatography. C. SDS-PAGE stained with
Coomassie Blue of fractions from E. coli cells: (U) uninduced cells; (I) induced with IPTG; (P) pelleted/insoluble fraction; (S) soluble fraction; (E) IMAC
eluate; and (S200) monomer fraction from Superdex 200 elution. 20 μg of total protein was loaded per lane. His6-SUMO-Gg-laforin runs as a
50 kDa species until removal of the His6-SUMO tag after IMAC elution (indicated by the arrow). Untagged Gg-laforin is predicted to be 36 kDa
(indicated by the asterisk). D. Dynamic light scattering was performed on a 1 mg/ml sample of Superdex 200-purified Gg-laforin monomer using
a Protein Solutions DynaPro-99 system. Scattering intensity was measured and presented as a fraction of the total protein mass. A single species
was detected with a hydrodynamic radius of 2.68 nm, corresponding to a molecular weight of 31.6±14.5 kDa.

Brewer et al. BMC Biochemistry 2014, 15:8
http://www.biomedcentral.com/1471-2091/15/8

using dynamic light scattering (DLS). The hydrodynamic
radius of the detected species corresponded to a 31.6 ±
14.5 kDa protein, the approximate size of the monomeric
Gg-laforin (Figure 3D). Cumulatively, these data demonstrate that Gg-laforin can be cleaved from the His6-SUMO
fusion tag, monomeric Gg-laforin can be resolved by sizeexclusion chromatography, and the monomers remain
monomeric during subsequent chromatography steps.
Thus, Gg-laforin behaves in a similar manner as previously
reported for Hs-laforin [7,8,30].
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(C266) to serine within the DSP of Hs-laforin inactivates
the enzyme [8,38]. We cloned and purified a corresponding
Gg-laforin C253S mutant, and as expected this mutant
displayed no activity and was used as a negative control.
Hs-laforin is the only human phosphatase known to
bind and dephosphorylate glycogen and amylopectin

I

A

S

P
VHR
Hs-laforin

Gg-laforin monomer binds glucans

Gg-laforin
pNPP activity

B
specific activity
(µmol min-1 mg-1)

8

Hs-laforin
Gg-laforin

6
4
2
0

5

6

pH

7

8

C dephosphorylation of amylopectin
2500

specific activity
(pmol min-1mg-1)

The CBM of Hs-laforin distinguishes this phosphatase
from other protein tyrosine phosphatase superfamily
members in that the CBM enables Hs-laforin to bind
carbohydrates [37]. Gg-laforin is predicted to possess a
CBM due to the high similarity between Hs-laforin and
Gg-laforin in this region. The CBM of Gg-laforin is
highly similar to the Hs-laforin CBM and was previously
shown to bind glycogen in vitro [34]. Using agarose
beads conjugated to the carbohydrate amylose, we investigated the glucan binding properties of Gg-laforin. The
Vaccinia H1-related phosphatase (VHR) is a human phosphatase from the same DSP superfamily as laforin, but
VHR lacks a CBM and is therefore unable to bind carbohydrates [8]. Hs-laforin, Gg-laforin and VHR were each incubated with amylose beads for 30 min at 4°C, the beads were
then pelleted by centrifugation, the supernatant was removed, and the beads were treated with SDS-PAGE buffer
to release the proteins bound to the beads. Subsequently,
proteins in the supernatant were precipitated and resuspended in SDS-PAGE buffer. Proteins in the supernatant
and pellet fractions were separated by SDS-PAGE and analyzed by Western blotting. Gg-laforin bound amylose to
the same extent as Hs-laforin, and both were present almost entirely in the pellet (Figure 4A). Alternatively, VHR
did not bind the amylose beads and remained in the supernatant as expected (Figure 4A). Thus, Gg-laforin possesses
a CBM that is capable of binding amylose to a similar degree as Hs-laforin.
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Another group reported that only Hs-laforin dimers possess phosphatase activity; however, work from our lab and
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of Hs-laforin are catalytically active [30,35]. To determine if
monomeric Gg-laforin has similar activity as Hs-laforin,
monomeric Gg-laforin was assayed for phosphatase activity
using the artificial substrate para-nitrophenylphosphate
(pNPP) over a range of pH values, from 5.0-8.0. Gg-laforin
displayed similar specific activity to Hs-laforin and also,
like Hs-laforin, displayed a preference for a lower pH
(Figure 4B). Mutation of the catalytic cysteine residue
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Figure 4 Analysis of carbohydrate binding and phosphatase
activity of Gg-laforin. A. His-tagged proteins were incubated with
amylose resin, then the amylose resin was pelleted by centrifugation,
the supernatant was removed, and SDS-PAGE buffer was added to
the pellet to release proteins bound to the amylose resin. Proteins in
the supernatant were precipitated, and SDS-PAGE buffer was added
to the supernatant sample. Protein input (I), supernatant (S) and
pellet (P) samples were resolved by SDS-PAGE and visualized by
Western analysis. B. Specific activities of Gg-laforin and Hs-laforin
were quantified against the artificial substrate pNPP at pH units
5.0-8.0. C. Phosphate release from amylopectin using Gg-laforin and
Hs-laforin at pH units 5.0-8.0 was measured using a malachite green
assay. Error bars indicate mean ± SD.
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in vitro [8,16,17]. Therefore, we investigated the ability
of Gg-laforin to dephosphorylate the phosphorylated
carbohydrate amylopectin using a malachite green-based
assay that detects liberated inorganic phosphate [29].
Gg-laforin possesses higher specific activity against
phosphorylated amylopectin than Hs-laforin, while preferring a similar pH to Hs-laforin (Figure 4C). These results demonstrate that Gg-laforin is a glucan phosphatase
and an ortholog of Hs-laforin, interestingly with a somewhat greater ability to dephosphorylate glucans than Hslaforin. At the optimal pH, Gg-laforin has a lower specific
activity against pNPP. Therefore, the two-fold increase in
the specific activity of phosphate release from amylopectin
may be due to differences in the CBM of Gg-laforin rather
than differences between Hs-laforin and Gg-laforin within
the DSP. Indeed, the Hs-laforin and Gg-laforin DSP domains share 84% similarity, while the CBM of Gg-laforin
is only 57% similar to the CBM of Hs-laforin [8]. However,
most of the amino acids associated with LD mutations are
conserved in the Gg-laforin CBM. These data show that
Gg-laforin is a glucan phosphatase with similar activity
levels as Hs-laforin, yet Gg-laforin is more soluble when
purified as a fusion protein in a bacterial expression system.

Conclusions
Human laforin has proven to be a difficult protein to
express in recombinant systems. These difficulties are
highlighted by previous reports that Hs-laforin must be
purified from inclusion bodies in E. coli or that only the
Hs-laforin CBM is soluble in E. coli [27,28]. While structural information regarding the individual laforin domains
would offer some insights into how laforin functions
as a glucan phosphatase, the more intriguing questions
focus on how the two domains are integrated and how
they function synergistically during dephosphorylation of
glycogen. Indeed, there are a number of structures of DSP
domains and CBMs already determined, but due to the
low degree of similarity with the laforin domains they do
not offer much insight into the function of laforin
[12,39-46]. We recently determined the structure of two
Arabidopsis glucan phosphatases, Starch EXcess 4 (SEX4)
and Like Sex Four 2 (LSF2). SEX4 contains a CBM and
DSP domain, while LSF2 lacks a CBM. The individual
laforin domains are likely to resemble the domains of
SEX4 and LSF2 [32,33]. Indeed, laforin is functionally related to SEX4 and LSF2 (i.e. they are all glucan phosphatases); however, the DSP of laforin is <39% similar to the
DSP of SEX4 and LSF2, and the laforin CBM is from an
entirely different sub-class of CBM than that of SEX4
[7,8,47-49]. Although SEX4 possesses a CBM and DSP,
these domains are in the opposite orientation compared
to laforin. SEX4 and LSF2 also each contain a C-terminal
motif that integrally folds into the DSP and is essential for
maintaining the integrity of the structure [32,33]. Although
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SEX4 and LSF2 are the first glucan phosphatase structures
to be determined, due to multiple differences in domain
organization as well as degree of similarity these structures
do not offer key insights into the structure of laforin.
Our lab has been successful in purifying sufficient
amounts of Hs-laforin for in vitro assays without using
denaturation and refolding steps, but recombinant Hslaforin has proved difficult to work with in experiments
requiring large quantities of protein, due to low yields and
the tendency to aggregate and precipitate. We sought a
laforin ortholog with greater solubility and stability yet
possessing similar in vitro characteristics as Hs-laforin;
such an ortholog would be a more conducive target for
crystallography and other biophysical techniques. The
structure of this ortholog would provide insight into the
mechanism of laforin function and may shed light on why
mutations in certain amino acids lead to LD.
We have demonstrated that His6-SUMO-Gg-laforin is
expressed as a soluble protein in E. coli, Gg-laforin remains soluble after cleavage of the fusion protein during
experimental manipulation, and it possesses both phosphatase and glucan binding activity. Gg-laforin can be
purified without the use of denaturation and refolding
steps, and the protein does not require a sugar to improve
its stability. We showed that Gg-laforin is present as a
multimer and monomer, it remains monomeric after sizeexclusion chromatography, and it possesses phosphatase
and glucan binding activity as a monomer. Monomeric
Gg-laforin has robust phosphatase activity against the
artificial substrate pNPP and also the more biologically
relevant substrate amylopectin, similar to the activity of
Hs-laforin as previously described [7,8,30]. Consequently,
Gg-laforin is an excellent alternative to Hs-laforin for
crystallization trials, and once determined, the structure of
Gg-laforin will be a very good model for Hs-laforin in
structure-function studies. The characterization of Gglaforin has provided an alternate route for obtaining the
crystal structure of laforin that can be utilized to clarify
the role of laforin in the metabolism of insoluble carbohydrates and the etiology of Lafora disease.

Methods
Cloning procedures

The ppSUMO plasmid was a generous gift from Dr. Jack
Dixon (University of California, San Diego, USA). The
plasmid pGL-EPM2A containing the gene for Mmlaforin (NP_034276.2) was a kind gift from Dr. Kazuhiro
Yamakawa (Brain Science Institute, Wako-shi, Japan).
Mm-laforin was subcloned into pET21a that includes a
C-terminal His6 tag.
Expressed sequence tags (ESTs) of Xt-laforin
(NP_001123695.1) and Gg-laforin (NP_001026240.1) were
purchased from Open Biosystems and Delaware Biotechnology Institute, respectively, and cloned into ppSUMO
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according to standard protocols. ppSUMO encodes a small
Ub-like modifier (SUMO) fusion tag that includes an
amino-terminal His6-tag to aid purification. Sequences were
verified by DNA sequencing. pET21a Vaccinia H1-related
phosphatase (VHR) and pET21a Hs-laforin constructs have
been described previously [8,38].
Protein expression and purification

All proteins were expressed in BL21-CodonPlus E. coli
cells (Stratagene) and purified using an IMAC column
on a Profinia purification system (BioRad) followed by
size exclusion chromatography. Bacterial cultures were
grown in 1 L 2xYT or Terrific Broth (IBI Scientific) with
1 mM kanamyacin and 1 mM chloramphenicol at 37°C
until OD600 reached ~0.8. Cultures were chilled on ice
for 20 minutes, and isopropyl thio-β-D-galactopyranoside (IPTG) was added for a final concentration of
0.4 mM to induce protein expression. After growth for
approximately 12-16 hours, cells were harvested by centrifugation and stored at -20°C. Bacterial pellets expressing Hs-laforin were resuspended in buffer A: 50 mM
Tris/HCl (pH 7.5), 300 mM NaCl, and 2 mM dithiothreitol
(DTT). Pellets expressing Mm-laforin were resuspended in
buffer B: 50 mM Tris/HCl (pH 8.0), 300 mM NaCl, and
0.05% β-mercaptoethanol. Pellets expressing VHR, Xtlaforin or Gg-laforin were resuspended in buffer C: 20 mM
Tris/HCl (pH 7.5), 100 mM NaCl and 2 mM DTT. 15%
maltose (w/v) or 10 mM β-cyclodextrin was added to some
preparations. Resuspended cells were lysed with a
microfluidizer (EmulsiFlex-C5, Avestin), and soluble
fractions were separated by high-speed centrifugation
(48,000 g). His6-SUMO-tagged Xt-laforin and Gg-laforin
were purified using a Profinia IMAC column (Bio-Rad)
with a Profinia protein purification system (Bio-Rad)
and dialyzed into buffer C in the presence of the SUMOspecific protease ULP1 that also contains a His6-tag. Reverse purification over the Profinia IMAC column was used
to remove ULP1-His6 and the fusion tag. Each protein
was then purified using a HiLoad 16/60 Superdex 200
size exclusion column and ÄKTA FPLC (GE Healthcare). Fractions containing the Gg-laforin monomer
species were collected and put back over the same
column. Mm-laforin, Hs-laforin and VHR were also
expressed as His6-tagged recombinant proteins and
purified in a similar manner.
Protein gel electrophoresis, quantitation of stability,
and dynamic light scattering

Protein purity was assessed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). Gels were
stained with Coomassie brilliant blue to visualize proteins.
To quantify stability of Hs-laforin and Gg-laforin, elution
fractions were concentrated using centrifugal filter units
(30 K, Amicon Ultra). Volume and concentration were
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monitored throughout centrifugation at 3,220 × g, and
protein concentration was measured using a Bradford
assay. To test long-term stability, samples were concentrated to approximately 2-4 mg/ml and incubated at
room temperature for eight days. Protein concentration
was monitored during the course of the experiment
using a Bradford assay.
Dynamic light scattering (Protein Solutions DynaPro99) was utilized to determine the hydrodynamic radius
of particles in solution. The DLS system measures the
size distribution of particles by detecting fluctuations in
light intensity over time. Scattering intensity was presented as a fraction of the total protein mass; poly- or
monodispersity in the sample was determined by the
number of peaks on the DLS histogram. A standard curve
embedded in the DLS software was used to calculate the
approximate size of a globular protein with the observed
hydrodynamic radius. Measurements were performed on
a protein sample of 1 mg/ml at room temperature.
Glucan binding assay

Amylose immobilized on agarose resin (New England
Biolabs) was pre-incubated with 1% BSA at room temperature for 30 min to prevent nonspecific binding. 0.25-1
μg of each recombinant His6-tagged protein was mixed
with 30 μl amylose beads in buffer C and protease inhibitor
cocktail (2.5 mM AEBSF, 2.5 mM benzamidine hydrochloride, 2.5 μM leupeptin, 2.5 μM E64) while rotating at
4°C for 30 min. Amylose beads were pelleted by centrifugation (2,300 × g), the supernatant was removed, proteins in
the supernatant were precipitated, and proteins in the
pellet and supernatant were visualized by Western analysis. Blots were probed with mouse anti-His6 1:4000
(NeuroMabs) and goat anti-mouse HRP (Invitrogen).
SuperSignal West Pico (Thermo Scientific) was used to
detect the HRP signal.
Phosphatase assays

Phosphatase activity was determined using the substrates
para-nitrophenylphosphate (pNPP) and potato amylopectin as described previously [8,29,30]. The pNPP reactions were carried out in 50 μl reactions in 1 ×
phosphate buffer (0.1 M sodium acetate, 0.05 M bisTris, 0.05 M Tris-HCl, and 2 mM DTT at the appropriate pH), 50 mM pNPP, and 200-400 μg enzyme at 37°C
for 2 min. Reactions were terminated with the addition
of 200 μl 0.25 M NaOH. Absorbance was measured at
410 nm. Malachite green reactions were carried out in
20 μl reactions in 1 × phosphate buffer, 45 μg amylopectin, and 100 ng enzyme at 37°C. After 2-5 minutes, 20 μl
0.1 M N-ethylmaleimide and 80 μl malachite green reagent was added to quench the reaction, and absorbances were measured at 620 nm after 40 minutes.
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Assays were performed in triplicate for each enzyme at
pH 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0.
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6.

7.

Sequence alignment

Amino acid sequences of laforin orthologs were obtained
from NCBI, aligned by ClustalW [50], and refined manually using MacVector. LD missense mutations are marked
according to listings in the Lafora Progressive Myoclonus
Epilepsy Mutation and Polymorphism database (http://
projects.tcag.ca/lafora/) [51].

8.

9.

10.

Additional file
Additional file 1: Figure S1. Multimerization of Xt-laforin. Xt-laforin
was purified by IMAC and passed over a HiLoad 16/60 Superdex 200 size
exclusion column. The chromatogram shows a prominent peak corresponding
to a multimeric species and unresolved peaks corresponding to the Xt-laforin
dimer and monomer (72 kDa and 36 kDa, respectively).
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